Severe neurological disabilities after complete remission of advanced malignant melanoma following fotemustine therapy in combination with total brain irradiation.
Gruss
C
C
Geissler
A
A
Schalke
B
B
Landthaler
M
M
Stolz
W
W
D018906:Antineoplastic Agents, Alkylating / Q000009:adverse effects* / Q000627:therapeutic use; D001284:Atrophy; D001921:Brain / Q000187:drug effects / Q000473:pathology / Q000528:radiation effects; D001925:Brain Damage, Chronic / Q000139:chemically induced / Q000209:etiology*; D001932:Brain Neoplasms / Q000150:complications / Q000188:drug therapy / Q000532:radiotherapy / Q000556:secondary*; D003131:Combined Modality Therapy; D016371:Cranial Irradiation / Q000009:adverse effects*; D003704:Dementia / Q000139:chemically induced / Q000209:etiology*; D006801:Humans; D008545:Melanoma / Q000150:complications / Q000188:drug therapy / Q000532:radiotherapy / Q000556:secondary*; D008875:Middle Aged; D009607:Nitrosourea Compounds / Q000009:adverse effects* / Q000627:therapeutic use; D009943:Organophosphorus Compounds / Q000009:adverse effects* / Q000627:therapeutic use; D010166:Palliative Care; D011788:Quality of Life; D011882:Radiotherapy, High-Energy / Q000009:adverse effects*; D012074:Remission Induction
D018906:Antineoplastic Agents, Alkylating; D009607:Nitrosourea Compounds; D009943:Organophosphorus Compounds; C054368:fotemustine